Trump Expands Drug Pricing Initiative With Drugmakers.

Trump is set to announce pricing agreements with nearly a dozen drugmakers Monday. The deals would have companies voluntarily sell medications at lower prices aligned with foreign rates.

• 17 companies, including Pfizer, Eli Lilly, and Novo Nordisk, have already signed MFN agreements.
• New deals would let state Medicaid programs receive discounts matching prices charged abroad.
• Companies that sign would be exempt from pilot programs requiring similar Medicare discounts.
• Prescription drug prices fell 3.1% year-over-year in July, the steepest annual drop in six decades.

Why it matters: U.S. prescription drug prices average nearly three times higher than overseas prices, and branded drug prices more than four times higher, according to a 2024 Rand Corp. study.

• Medicaid is already required by law to receive significant discounts, making patient out-of-pocket impact uncertain.
• The announcements come ahead of November midterm elections, as the White House spotlights healthcare affordability.

How 25 sources split on this story

Where they split: The core dispute is whether the MFN deals meaningfully lower costs for patients or are primarily a political messaging tool ahead of midterms.

What’s next: State Medicaid programs must decide individually whether to participate, as participation is optional.

• Drugmakers are investing billions to shift manufacturing to the U.S., partly to hedge against tariff threats.
• Which specific companies are included in Monday's announcement has not been confirmed.
• Whether the new Medicaid-aligned discounts will change what patients actually pay out of pocket remains unclear.
• How PhRMA and pharmacy benefit managers respond to the expanded MFN framework is unknown.